AstraZeneca: Tagrisso included in the National Reimbursement Drug List for the first time

On November 14, AstraZeneca announced that Tezspire (tezepelumab), an innovative biologic in the respiratory field, has been included in the National Basic Medical Insurance Drug List for the first time. In March 2026, tezepelumab was approved in China and officially launched in August of the same year for the maintenance treatment of severe asthma in adults and adolescents aged 12 years and older, and for use in combination with intranasal corticosteroids for the treatment of adult patients with chronic rhinosinusitis with nasal polyps whose disease cannot be adequately controlled with systemic corticosteroids and/or surgery.